FERRIC CARBOXYMALTOSE | N203565 | AMERICAN REGENT INC
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2015-01490 | 7754702 | IPR | Pharmacosmos A/S | Final Written Decision | 2015-06-24 | — |
| IPR2015-01495 | 8895612 | IPR | Pharmacosmos A/S | Institution Denied | 2015-06-24 | — |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
VIFOR (INTERNATIONAL) AG et al v. XIROMED PHARMA ESPANA, S.L. et al 6 patentsANDA 220469ferric carboxymaltose | D.N.J. | 2025-11-21 | Active | — |
Vifor (International) AG et al v. Orbicular Pharmaceutical Technologies Private Limited 6 patentsANDA 212136ferric carboxymaltose | D.N.J. | 2025-10-20 | Active | — |
Vifor (International) AG et al v. Orbicular Pharmaceutical Technologies Pvt. Ltd. 5 patentsANDA 212136ferric carboxymaltose | D.N.J. | 2025-09-08 | Active | — |
Vifor (International) AG et al v. Orbicular Pharmaceutical Technologies Private Limited 6 patentsANDA 212136ferric carboxymaltose | D. Del. | 2025-08-21 | Terminated 2025-10-17 | — |
Vifor (International) AG et al v. Orbicular Pharmaceutical Technologies Pvt. Ltd. 5 patentsANDA 212136ferric carboxymaltose | D. Del. | 2025-05-02 | Terminated 2025-09-05 | — |
VIFOR (INTERNATIONAL) AG et al v. MSN LABORATORIES PRIVATE LIMITED et al 6 patentsANDA 219580ferric carboxymaltose | D.N.J. | 2025-04-25 | Terminated 2025-07-16 | — |
Vifor (International) AG et al v. Apotex Inc. et al 6 patentsANDA 219993ferric carboxymaltose | D. Del. | 2025-02-20 | Active | — |
| D.N.J. | 2020-02-14 | Terminated 2020-02-24 | — | |
VIFOR (INTERNATIONAL) AG et al v. MYLAN LABORATORIES LTD. 5 patentsANDA 212572ferric carboxymaltose | D.N.J. | 2020-02-14 | Terminated 2020-02-24 | — |
| D.N.J. | 2019-08-02 | Terminated 2020-02-06 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Luitpold Pharmaceuticals Inc. (Sheppard, Mullin, Richte... FDA-2013-P-1294 On September 30, 2013, Luitpold Pharmaceuticals Inc., through counsel at Sheppard Mullin Richter & Hampton LLP, filed a citizen petition requesting that the FDA approve any New Drug Application or supplement for injectable iron products treating iron deficiency anemia outside chronic kidney disease | 505(q) | 2013-11-15 | Denied | Luitpold Pharmaceuticals Inc. (Sheppard |
Source: Regulations.gov. FDA citizen petitions matched by application number.